Vaccination of pneumococcal infection in patients with systemic lupus erythe matosus and antiphospholipid syndrome: experience of 6 years of use
Infections remain one of the main causes of morbidity and mortality in patients with immuno-inflammatory rheumatic diseases. Objective – to study the efficacy, immunogenicity and safety of the 23-valent polysaccharide pneumococcal vaccine (PPV-23) in patients with systemic lupus erythematosus (SLE)...
Saved in:
Main Authors: | G. M. Tarasova, B. S. Belov, T. M. Reshetnyak, M. V. Cherkasova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA PRESS LLC
2023-06-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/3360 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety and efficacy of 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus
by: G. M. Tarasova, et al.
Published: (2021-06-01) -
INVESTIGATION OF IMMUNOGENICITY AND SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
by: G. M. Tarasova, et al.
Published: (2018-09-01) -
Immunogenicity, Tolerability, and Clinical Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine in Patients with Systemic Lupus Erythematosus
by: G. M. Tarasova, et al.
Published: (2020-08-01) -
ANTIPHOSPHOLIPID SYNDROME: DIAGNOSIS AND CLINICAL MANIFESTATIONS (A LECTURE)
by: Tat’yana M Reshetnyak
Published: (2014-03-01) -
Global antiphospholipid syndrome score (GAPSS) in patients with systemic lupus erythematosus
by: F. A. Cheldieva, et al.
Published: (2022-11-01)